MYLOTARG (gemtuzumab ozogamicin)

AML, acute myeloid leukaemia; EFS, event-free survival; OS, overall survival; RFS, relapse-free survival.

References:
1. Pfizer MYLOTARGTM (gemtuzumab ozogamicin) Summary of Product Characteristics.
2. Pfizer Cytarabine Summary of Product Characteristics
3. Lambert J, et al. Haematologica 2019;104:113–119

PP-MYL-IRL-0037 Date of Preparation September 2021 Legal Category: S1A